BRIEF-Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk For LX9851

Reuters03-28

March 28 (Reuters) - Lexicon Pharmaceuticals Inc LXRX.O:

LEXICON PHARMACEUTICALS ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH NOVO NORDISK FOR LX9851
LEXICON PHARMACEUTICALS INC - ELIGIBLE FOR UP TO $75 MILLION IN UPFRONT AND NEAR-TERM MILESTONE PAYMENTS
LEXICON PHARMACEUTICALS INC - ELIGIBLE FOR $1 BILLION IN TOTAL PAYMENTS
LEXICON PHARMACEUTICALS INC - ENTITLED TO TIERED ROYALTIES ON NET SALES OF LX9851
LEXICON - NOVO NORDISK WILL BE RESPONSIBLE FOR FILING IND, ALL FURTHER DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF LX9851

Source text: ID:nGNX4hDsrs

Further company coverage: LXRX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2522578447?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-28 19:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522578447","market":"us","top_or_hot":-1,"title":"BRIEF-Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk For LX9851","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk For LX9851</title></head><body><p><span>March 28 (Reuters)</span><span> - </span>Lexicon Pharmaceuticals Inc <span>LXRX.O</span>:</p><ul><li><p>LEXICON PHARMACEUTICALS ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH NOVO NORDISK FOR LX9851</p></li><li><p>LEXICON PHARMACEUTICALS INC - ELIGIBLE FOR UP TO $75 MILLION IN UPFRONT AND NEAR-TERM MILESTONE PAYMENTS</p></li><li><p>LEXICON PHARMACEUTICALS INC - ELIGIBLE FOR $1 BILLION IN TOTAL PAYMENTS</p></li><li><p>LEXICON PHARMACEUTICALS INC - ENTITLED TO TIERED ROYALTIES ON NET SALES OF LX9851</p></li><li><p>LEXICON - NOVO NORDISK WILL BE RESPONSIBLE FOR FILING IND, ALL FURTHER DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF LX9851</p></li></ul><p>Source text: <span>ID:nGNX4hDsrs</span></p><p>Further company coverage: <span>LXRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk For LX9851</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk For LX9851\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-28 19:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk For LX9851</title></head><body><p><span>March 28 (Reuters)</span><span> - </span>Lexicon Pharmaceuticals Inc <span>LXRX.O</span>:</p><ul><li><p>LEXICON PHARMACEUTICALS ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH NOVO NORDISK FOR LX9851</p></li><li><p>LEXICON PHARMACEUTICALS INC - ELIGIBLE FOR UP TO $75 MILLION IN UPFRONT AND NEAR-TERM MILESTONE PAYMENTS</p></li><li><p>LEXICON PHARMACEUTICALS INC - ELIGIBLE FOR $1 BILLION IN TOTAL PAYMENTS</p></li><li><p>LEXICON PHARMACEUTICALS INC - ENTITLED TO TIERED ROYALTIES ON NET SALES OF LX9851</p></li><li><p>LEXICON - NOVO NORDISK WILL BE RESPONSIBLE FOR FILING IND, ALL FURTHER DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF LX9851</p></li></ul><p>Source text: <span>ID:nGNX4hDsrs</span></p><p>Further company coverage: <span>LXRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nTUAC1H3XW:1","article_id":"2522578447","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522578447","pubTimestamp":1743162596,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk For LX9851March 28 (Reuters) - Lexicon Pharmaceuticals Inc LXRX.O:LEXICON PHARMACEUTICALS ANNOUNCES EXCLUSIVE LICE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"简报-Lexicon Pharmaceuticals宣布与诺和诺德就LX9851达成独家许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LXRX":0.9},"content_text":"BRIEF-Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk For LX9851March 28 (Reuters) - Lexicon Pharmaceuticals Inc LXRX.O:LEXICON PHARMACEUTICALS ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH NOVO NORDISK FOR LX9851LEXICON PHARMACEUTICALS INC - ELIGIBLE FOR UP TO $75 MILLION IN UPFRONT AND NEAR-TERM MILESTONE PAYMENTSLEXICON PHARMACEUTICALS INC - ELIGIBLE FOR $1 BILLION IN TOTAL PAYMENTSLEXICON PHARMACEUTICALS INC - ENTITLED TO TIERED ROYALTIES ON NET SALES OF LX9851LEXICON - NOVO NORDISK WILL BE RESPONSIBLE FOR FILING IND, ALL FURTHER DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF LX9851Source text: ID:nGNX4hDsrsFurther company coverage: LXRX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2522578447"}